. 2018 Jun 30;8(6):e020427. doi: 10.1136/bmjopen-2017-020427

Table 1.

Summary table of included studies

Author/year	Study type	Study population	Patient no (P:NP)	Patient demographics (mean age, M:F ratio)		Epigenetic analysis	Markers analysed	Result
Agarwal et al 2012⁴⁶	Retrospective cohort	Pathology archives at Baltimore Veteran’s Affairs Medical Centre and Johns Hopkins University School of Medicine	9 (5:4)	Not stated		CpG methylation (244K human CpG microarray)	Extragenic x 3	0.45—relative CpG methylation
							Intra_BCL11B	0.17
							Intra_CCDC57	0.23
							Intra_F10	1.86
							Pro_CKB	0.83
							Pro_ELAVL3-ZNF653	0.6
							Pro_GPR177	0.7
							Pro_HOXB7	0.67
							Pro_IGF1R	0.58
							Pro_ITGB8	0.55
							Pro_JARID 1B	0.35
							Pro_JUND	0.54
							Pro_LAMA5	0.45
							Pro_LOC55565	0.76
							Pro_MGC35308	0.52
							Pro_MMD2	1.34
							Pro_TAF10	0.43
							Pro_TLX3	0.31
							Pro_UBP1	0.71
							Pro_WNK4	0.76
							Pro_WWC1	0.68
							Pro_ZBTB7B	0.56
							Pro_ZNF358	1.25
Barrett et al 1999³⁷	Retrospective cohort	Fred Hutchinson Cancer Research Centre+University of Washington	31 (25:6)	Not stated		CpG methylation (methylation-specific PCR)	CDKN2A	Hypermethylation in premalignant samples
Boerwinkel et al 2014⁴³	Retrospective cohort	AMC BO Surveillance	44 (48:10)	Mean age=6632M:12F		CpG methylation (methylight methylation-specific PCR)	HPP1	NS
							p16	P hypermethylated
							RUNX3	NS
Clément et al 2006³⁵	Retrospective cohort	Lausanne, Switzerland	28* (12:16)	Not stated		CpG methylation (methylation-specific PCR)	APC	P hypermethylated
							CDKN2A	NS
							SFRP1	Hypermethylated in all samples P and NP
							TIMP3	P hypermethylated
							TERT	P hypermethylated
Clément et al 2008³⁴	Retrospective cohort	Lausanne, Switzerland	31 (16:15)	Not stated		CpG methylation (methylation-specific PCR)	WIF-1	P hypermethylated
Eads et al 2001⁴⁴	Retrospective cohort	Norris Comprehensive Cancer Centre	20 (12:8)	Not stated		CpG methylation (methylight methylation-specific PCR)	CALCA	P hypermethylated
							CDKN2A	P hypermethylated
							ESR1	P hypermethylated
							MGMT	P hypermethylated
							MYOD1	P hypermethylated
							TIMP3	P hypermethylated
Jin et al 2009⁴¹	Case control	Five participating US clinics	195* (50:145)	P significantly older than NP		CpG methylation (methylation-specific PCR)	HPP1	P hypermethylated
							p16	P hypermethylated
							RUNX3	P hypermethylated
							CDH13	NS
							TAC1	NS
							NELL1	NS
							AKAP12	NS
							SST	NS
Klump et al 1998³⁶	Retrospective cohort	Under routine Barrett’s surveillance	14 (10:4)	P mean age 57.48M:2F	NP mean age 553M:1F	CpG methylation (methylation-specific PCR)	p16	P hypermethylated
Moinova et al 2012⁴²	Retrospective cohort	Retrospective collection from pathology database	5 (2:3)	Not stated		CpG methylation (methylation-specific PCR)	VIM	VIM methylation present in NDBO, not relevant in progression
Puertas Canteria 2012⁴⁵	Retrospective cohort	No details	55 (6:14)	Not stated		CpG methylation (bisulfite pyrosequencing)	p16	Methylation P 12.04% versus NP 6.53%
Revilla-Nuin et al 2013³³	Retrospective cohort	1982 trial assessing medical versus surgical therapy for prevention of progression of BO. Randomly selected	5 (7:17)	Not stated		miRNA expression analysis	miR-192	Overexpressed AUROC 0.61
							miR-194	Overexpressed AUROC 0.70
							miR-196a	Overexpressed AUROC 0.80
							miR-196b	Overexpressed AUROC 0.74
Sato et al 2008⁴⁰	Retrospective cohort	MAYO and UMD mixed cohort	62 (28:34)	Not stated		CpG methylation (methylation-specific PCR)	HPP1	P hypermethylated
							p16	P hypermethylated
							RUNX3	P hypermethylated
Schulmann et al 2005³⁹	Retrospective cohort	Baltimore Veteran’s Affairs hospitals and University of Maryland Hospitals	53 (8:45)	P mean age 63.34M:0F, segment length 10.0 cm	NP mean age 62.235M:3F, segment length 5.8 cm	CpG methylation (methylation-specific PCR)	RUNX3	P hypermethylated
							HPP1	P hypermethylated
							p16	P hypermethylated
							CRBP1	Hypermethylation not independently associated with P
							TIMP3	Hypermethylation not independently associated with P
							APC	Hypermethylation not independently associated with P
Wang et al 2009³⁸	Retrospective cohort	Johns Hopkins under surveillance for GORD/BO	57 (7:50)	No significant differences in N versus NP. Data not provided		CpG methylation (methylation-specific PCR)	APC	P hypermethylated
Wang et al 2009³⁸	Retrospective cohort	Johns Hopkins under surveillance for GORD/BO	57 (7:50)			CpG methylation (methylation-specific PCR)	p16	P hypermethylated

*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).

AUROC, area under receiver operating characteristic; BO, Barrett’s Oesophagus; GORD, gastro-oesophageal reflux disease; M:F, male-to-female ratio; miRNA, micro RNA; NDBO, non-dysplastic BO; NP, non-progressing patients; NS, not statistically significant; P, progressing patients; PLSD, protected least significant difference; ROC, receiver operating characteristic.